Advanced Proteome Therapeutics (STU:0E81) General and Admin. Expense: €0.32 Mil (TTM As of Apr. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Advanced Proteome Therapeutics General and Admin. Expense?

Advanced Proteome Therapeutics STU:0E81 General and Admin. Expense is €0.32 Mil as of Apr. 2023.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Advanced Proteome Therapeutics's General and Admin. Expense for the three months ended in Apr. 2023 was €0.05 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Apr. 2023 was €0.32 Mil.

Advanced Proteome Therapeutics General and Admin. Expense Related Terms

Advanced Proteome Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Advanced Proteome Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics General and Admin. Expense Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 0.79 0.48 0.22 0.25

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.09 0.08 0.10 0.05

Advanced Proteome Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Apr. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €0.32 Mil mean?
Advanced Proteome Therapeutics (STU:0E81) has a General and Admin. Expense of €0.32 Mil as of Apr. 2023. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Advanced Proteome Therapeutics and its competitors.
Is Advanced Proteome Therapeutics' General and Admin. Expense too high?
Advanced Proteome Therapeutics' current General and Admin. Expense is €0.32 Mil.
How does Advanced Proteome Therapeutics' General and Admin. Expense compare to VRTX and REGN?
Advanced Proteome Therapeutics' General and Admin. Expense of €0.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Advanced Proteome Therapeutics and its competitors. Advanced Proteome Therapeutics's current General and Admin. Expense is €0.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Proteome Therapeutics stock overvalued right now?
Advanced Proteome Therapeutics (STU:0E81) has a current General and Admin. Expense of €0.32 Mil. The current General and Admin. Expense is €0.32 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Advanced Proteome Therapeutics (STU:0E81), the current General and Admin. Expense is €0.32 Mil as of Apr. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Proteome Therapeutics Business Description

Address 104 8337 Eastlake Drive, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.